Understanding peptide self-assembly mechanisms and stability of the formed assemblies is crucial for the development of functional nanomaterials. Herein, we have adopted a rational design approach to demonstrate how a minimal structural modification to a nonassembling ultrashort ionic selfcomplementary tetrapeptide FEFK (Phe4) remarkably enhanced the stability of self-assembly into β-sheet nanofibers and induced hydrogelation. This was achieved by replacing flexible phenylalanine residue (F) by the rigid phenylglycine (Phg), resulting in a constrained analogue PhgEPhgK (Phg4), which positioned aromatic rings in an orientation favorable for aromatic stacking. Phg4 self-assembly into stable β-sheet ladders was facilitated by π-staking of aromatic side chains alongside hydrogen bonding between backbone amides along the nanofiber axis. The contribution of these noncovalent interactions in stabilizing self-assembly was predicted by in silico modeling using molecular dynamics simulations and semiempirical quantum mechanics calculations. In aqueous medium, Phg4 β-sheet nanofibers entangled at a critical gelation concentration ≥20 mg/mL forming a network of nanofibrous hydrogels. Phg4 also demonstrated a unique surface activity in the presence of immiscible oils and was superior to commercial emulsifiers in stabilizing oil-in-water (O/W) emulsions. This was attributed to interfacial adsorption of amphiphilic nanofibrils forming nanofibrilized microspheres. To our knowledge, Phg4 is the shortest ionic self-complementary peptide rationally designed to self-assemble into stable β-sheet nanofibers capable of gelation and emulsification. Our results suggest that ultrashort ionic-complementary constrained peptides or UICPs have significant potential for the development of cost-effective, sustainable, and multifunctional soft bionanomaterials.

No abstract

Viral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strategy to control such viral infections, with the successful and recently accelerated development of different types of vaccines, thanks to the advanced biotechnological techniques involved in the upstream and downstream processing of these products. However, there is still much work to be done for the improvement of efficacy and safety when it comes to the choice of delivery systems, formulations, dosage form and route of administration, which are not only crucial for immunisation effectiveness, but also for vaccine stability, dose frequency, patient convenience and logistics for mass immunisation. In this review, we discuss the main vaccine delivery systems and associated challenges, as well as the recent success in developing nanomaterials-based and advanced delivery systems to tackle these challenges. Manufacturing and regulatory requirements for the development of these systems for successful clinical and marketing authorisation were also considered. Here, we comprehensively review nanovaccines from development to clinical application, which will be relevant to vaccine developers, regulators, and clinicians.

It is well acknowledged that carbon nanotubes (CNTs) are a potential new class of nanomaterials for technological advancement. The recent discovery of diverse kinds of carbon nanostructures has sparked interest in the potential applications of these materials in a variety of disciplines. Numerous distinct carbon nanotube (CNT) production methods have been developed, and their characterisation, separation, and manipulation of individual CNTs are now possible. Structure, surface area, surface charge, size distribution, surface chemistry, aggregation state, and purity of the samples all have a significant impact on the reactivity of carbon nanotubes, as does the purity of the samples. Currently, carbon nanotubes (CNTs) are being successfully used in the medicinal, pharmaceutical, and biomedical fields because of their large surface area, which makes them capable of adsorbing or conjugating with a wide range of therapeutic and diagnostic substances (drugs, genes, vaccines, antibodies, biosensors, etc.). They were the first to demonstrate that they are a great vehicle for drug delivery straight into cells without the need for metabolic processing by the body. This paper discusses the different types, structures, and properties of CNTs, as well as CNT synthesis and purification methods, how to functionalize CNTs, and their application in medicinal, pharmaceutical, and biomedical fields, toxicological properties and their assessment, as well as in-vivo pharmacology and biodegradation pathways.